Inicio


Publicación

What's New in the Treatment of Enterococcal Endocarditis?


Información de la publicación

Información de la publicación
Tipo de publicación

Científica

Tipología

Investigación y estudios

Medio de publicación

Digital: Revista digital

Resumen

Enterococcus spp. are among the common pathogens causing infective endocarditis (IE). Despite major medical advances and new potent antimicrobial agents, the mortality has not significantly improved for several decades. The usual lack of bactericidal activity of penicillin or ampicillin, the toxicity from the combination of penicillin plus aminoglycosides, and the increased reports of high-level resistance to aminoglycosides have led to the exploration of other regimens for treatment of Enterococcus faecalis IE. As an example, ampicillin plus ceftriaxone is now a well-recognized regimen for this organism. However, the emerging of new drug resistances in Enterococcus faecium dramatically reduces the therapeutic alternatives for this organism in IE which continues to be an immense challenge for clinicians even with the availability of newer antimicrobial agents. This article summarizes the current treatment options for enterococcal endocarditis and reviews of recent publications on the topic

Autores

Nigo M, Munita JM, Arias CA, Murray BE.

Registro ISSN

1534-3146 (Electronic)

SNIES Área

Immunology and Microbiology

SNIES Categoría

Infectious Diseases

Fecha de publicación 08 de febrero de 2017
Fecha de aceptación 08 de febrero de 2017
Medio indexado (nombre)

Current infectious disease reports

Bases de datos donde está referenciada

Pubmed

English information
Title

What's New in the Treatment of Enterococcal Endocarditis?

Abstract

Enterococcus spp. are among the common pathogens causing infective endocarditis (IE). Despite major medical advances and new potent antimicrobial agents, the mortality has not significantly improved for several decades. The usual lack of bactericidal activity of penicillin or ampicillin, the toxicity from the combination of penicillin plus aminoglycosides, and the increased reports of high-level resistance to aminoglycosides have led to the exploration of other regimens for treatment of Enterococcus faecalis IE. As an example, ampicillin plus ceftriaxone is now a well-recognized regimen for this organism. However, the emerging of new drug resistances in Enterococcus faecium dramatically reduces the therapeutic alternatives for this organism in IE which continues to be an immense challenge for clinicians even with the availability of newer antimicrobial agents. This article summarizes the current treatment options for enterococcal endocarditis and reviews of recent publications on the topic

Keywords

therapeutic alternatives, Enterococcus, Endocarditis, resistance

Información de contacto

Contacto de Publicaciones